GRDX — GridAI Technologies Share News
0.000.00%
Last trade - 00:00- $39.97m
- $45.06m
- $0.04m
Brief: First Wave Biopharma Announces $4.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Brief: First Wave Biopharma Doses Second Patient In Phase 2 Trial Of Cystic Fibrosis Drug
U.S. STOCKS ON THE MOVE-Vertex Pharma, Duluth, Molecular Templates
U.S. STOCKS ON THE MOVE-BJ's Wholesale, FuelCell Energy, Holley
First Wave soars on starting patient dosing in pancreatic disorder drug trial
Brief: First Wave Biopharma Announces First Patient Dosed In Phase 2 Trial Of Enhanced Adrulipase Formulation
Brief: First Wave Biopharma Announces Phase 2 Adrulipase Combination Trial Data To Be Presented At The 2023 Digestive Disease Week (Ddw) Conference
Brief: First Wave Biopharma Regains Compliance With Nasdaq’S Minimum Bid Price Requirement
Brief: First Wave BioPharma Announces First Patient Screened For Phase 2 Span Adrulipase Trial
Brief: First Wave BioPharma Announces Initiation Of Phase 2 Trial Of Enhanced Adrulipase Formulation
First Wave files patent application for pancreatic disorder drug, shares rise
Brief: First Wave BioPharma Announces Expansion Of Adrulipase Portfolio
Brief: First Wave Biopharma Provides Update On Ind Filing For Phase 2 Trial Of Enhanced Microgranule Formulation Of Adrulipase For Exocrine Pancreatic Insufficiency
First Wave up as FDA reviews pancreatic drug trial application
Brief: First Wave Biopharma - On Dec 20, Co Received Letter From Panel Confirming That Co Had Regained Compliance With Minimum Stockholders' Equity Rule - Filing
Brief: First Wave Biopharma Inc - On Dec 14, Co Received Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard From Nasdaq
Brief: First Wave BioPharma Announces Initial Clinical Sites For Its Phase 2 Trial Of Enhanced Microgranule Delivery Formulation Of Adrulipase
Brief: First Wave Biopharma Files Prospectus Related To Resale Of Up To 12.5 Million Shares - SEC Filing
U.S. STOCKS ON THE MOVE-Viridian, Carvana, Titan Machinery